230 related articles for article (PubMed ID: 27701921)
1. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.
Yanagi Y; Fukuda A; Barzey V; Adachi K
J Med Econ; 2017 Feb; 20(2):204-212. PubMed ID: 27701921
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
6. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
[TBL] [Abstract][Full Text] [Related]
7. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.
Claxton L; Hodgson R; Taylor M; Malcolm B; Pulikottil Jacob R
Pharmacoeconomics; 2017 Feb; 35(2):237-248. PubMed ID: 27787744
[TBL] [Abstract][Full Text] [Related]
8. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
[No Abstract] [Full Text] [Related]
9. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
Elshout M; van der Reis MI; Webers CA; Schouten JS
Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
Ruiz Ramos J; Pascual-Camps I; Cuéllar-Monreal MJ; Dolz-Marco R; Fenoll MA; Font-Noguera I; Poveda-Andrés JL; Gallego-Pinazo R
Arch Soc Esp Oftalmol; 2015 Dec; 90(12):566-71. PubMed ID: 26515015
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC
PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
Earnshaw SR; Moride Y; Rochon S
Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
[TBL] [Abstract][Full Text] [Related]
15. The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK.
Ghosh W; Wickstead R; Claxton L; Kusel J; Taylor M; Fleetwood K; Pulikottil-Jacob R
Adv Ther; 2016 Sep; 33(9):1660-76. PubMed ID: 27457470
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
Holekamp N; Duff SB; Rajput Y; Garmo V
J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
[No Abstract] [Full Text] [Related]
17. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund KB; Hoang QV; Saroj N; Thompson D
Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy.
Doble B; Finkelstein EA; Tian Y; Saxena N; Patil S; Wong TY; Cheung CMG
JAMA Ophthalmol; 2020 Mar; 138(3):251-259. PubMed ID: 31917395
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
